FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel peptide analogues of oxyntomodulin, their pharmaceutical compositions and their application for treatment and/or prevention of excessive weight, as well as disorders and diseases, accompanying obesity.
EFFECT: peptide finds special application as appetite suppressor and in treatment of obesity.
30 cl, 41 dwg, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
